Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.


Alan Franciscus

Editor-in-Chief

HCV Advocate


Showing posts with label liver disease. Show all posts
Showing posts with label liver disease. Show all posts

Wednesday, March 18, 2015

Hepatitis C and the Baby Boomer Generation

As the Centers for Disease Control and Prevention release new guidelines regarding testing baby boomers - St. Luke' s Magic Valley is putting a new initiative in place.

"Three quarters of all patients with Hep. C in fact are baby boomers. Unfortunately more than three quarters of them are unknown to us," explained Dr. Brian Berk, Gastroenterologist, St. Luke’s Magic Valley.

Hepatitis C is a contagious liver disease that ranges in severity. It's spread primarily through contact with the blood of an infected person.

Read more...
Posted by at No comments:
Labels: , , , ,

Hepatitis C Therapeutic Development and Pipeline Review H1 2015 Research Report

RnRMarketResearch.com adds "Hepatitis C - Pipeline Review, H1 2015" therapeutic market research report of 639 pages with latest updates, data and information to its online business intelligence library.
The report "Hepatitis C - Pipeline Review, H1 2015" provides an overview of the Hepatitis C's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects.
Hepatitis C is a liver disease caused by the hepatitis C virus. The virus can cause both acute and chronic hepatitis infection, ranging in severity from a mild illness lasting a few weeks to a serious, lifelong illness. There are many types of hepatitis C virus. The most common in the U.S. is type 1. No type is more serious than any other, but they respond differently to treatment. Hepatitis C is an increasing public health concern in the United States and throughout the world. Symptoms of Hepatitis C include jaundice, stomach pain, loss of appetite, nausea and fatigue. 3, 50,000 to 5, 00,000 people die each year from hepatitis C-related liver diseases. 

Posted by at 1 comment:
Labels: , , ,
Subscribe to: Posts (Atom)